CRBP
CorbusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
CRBP has multiple 2026 shots on goal: ASCO monotherapy data for CRB-701, potential mid-2026 registrational-study initiation after FDA alignment, and summer Phase 1b CRB-913 data, while company guidance suggests runway into 2028 [#PR-2026-04-07] [#PR-2026-04-14] [#PR-2026-03-09].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.7.
What can break
ASCO 2026 CRB-701 data may fail to show enough durability or subgroup strength to support the emerging registrational narrative [#PR-2026-04-07].
Momentum
24
Value
41
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $18.00 · Bear $5.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $35.30
Why
Momentum24 · Δ7d +0.1
Value41 · Δ7d +0.0
Sentiment57 · Δ7d +3.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
24
26% active weight
Current posture
7d trendImproving
Δ7d
+0.1
Δ21d
+11.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
57
34% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
-5.2
Why this grade
Composite grade D. Momentum 24.2 / Value 41.1 / Sentiment 57.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$166.94M
Beta
2.87
Shares Out
18.53M
P/E (TTM) · Derived
-1.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.82
Rev YoY
-100.0%
EPS YoY
-11.8%
Gross Margin
-
Op Margin
-
Net Debt
-$162.31M
Current Ratio
7.92
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology